GIKLY — Grifols SA
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1438569 ·
Last close
$5.55
Market Cap
$4.69B
52W High
$6.68
52W Low
$5.01
ADV30
0
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 2,040,000,000 | 807,000,000 | 394,000,000 | 162,000,000 | 20,281,000,000 | 486,000,000 | 12,038,000,000 |
| Jun 2026 | 1,874,000,000 | 705,000,000 | 329,000,000 | 155,000,000 | 20,090,000,000 | 513,000,000 | 12,110,000,000 |
| Mar 2026 | 1,700,000,000 | 620,000,000 | 249,000,000 | 73,000,000 | 20,078,000,000 | 702,000,000 | 12,231,000,000 |
| Dec 2025 | 1,981,660,000 | 686,841,000 | 275,377,000 | 98,250,000 | 19,712,000,000 | 801,000,000 | 12,109,000,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$1,117,864,000
Investing CF
$-538,321,000
Financing CF
$-737,176,000
CapEx
$-453,149,000
Dividends Paid
$-187,618,000
Buybacks
—
EPS Diluted TTM
$0.38
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$390,000,000
Inventory
$3,469,000,000
Receivables
$1,079,000,000
ST Investments
$209,000,000
EBIT TTM
$1,188,087,000
Pretax Income TTM
$708,096,000
Interest Exp TTM
$558,421,000
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$7,421,000,192
EBITDA
$1,645,230,976
Free Cash Flow
$572,923,392
Enterprise Value
$19,074,234,368
Total Cash
$537,000,000
Total Debt
$9,356,000,256
Shares Out
844,714,130
Trailing EPS
$0.38
Book Value
$4.72
ROE
6.9%
ROA
4.2%
Div Yield
0.82%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 7,524,000,000 | 1,251,000,000 | 402,000,000 | 19,712,000,000 | 12,109,000,000 | 5,271,000,000 | 1,047,000,000 |
| Dec 2024 | 7,212,000,000 | 1,155,000,000 | 157,000,000 | 21,405,000,000 | 12,799,000,000 | 5,883,000,000 | 902,000,000 |
| Dec 2023 | 6,592,000,000 | 718,000,000 | 42,000,000 | 20,992,103,000 | 13,478,408,000 | 5,368,376,000 | 217,000,000 |
| Dec 2022 | 6,063,967,000 | 678,958,000 | 185,035,000 | 21,229,584,000 | 13,253,455,000 | 5,648,523,000 | -1,427,000 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| KNSA | Kiniksa Pharmaceuticals International, plc | $4.64B | $95.11 | — |
| EWTX | Edgewise Therapeutics, Inc. | $4.60B | $42.04 | — |
| COGT | Cogent Biosciences, Inc. | $4.85B | $27.85 | — |
| ERAS | Erasca, Inc. | $4.87B | $13.89 | — |
| IONS | IONIS PHARMACEUTICALS INC | $4.49B | $26.96 | — |
News headlines (Yahoo Finance, 1h cache)
ADMA Surges 20.9% Post Q3 Earnings: Buy, Sell or Hold the Stock?
2026-11-11 16:41 · Yahoo
European Equities Traded in the US as ADRs Tick Higher in Wednesday Trading
2026-11-11 16:12 · Yahoo
Rigel Pharmaceuticals Inc (RIGL) (Q3 2026) Earnings Call Highlights: Record Product Sales of ...
2026-11-06 19:14 · Yahoo
European Equities Traded in the US as American Depositary Receipts Advance Sharply in Wednesday Trading
2026-11-04 16:13 · Yahoo
Grifols (BME:GRF) Stock Price Trails Q3 Results As Debt Questions Linger
2026-11-03 19:11 · Yahoo
Grifols Beats Q3 Revenue Forecasts as Immunoglobulin Demand Supports Profit Growth
2026-11-03 11:17 · Yahoo
Grifols SA (GRFS) Q3 2026 Earnings Call Highlights: Biopharma Growth Accelerates as Margin ...
2026-11-03 05:03 · Yahoo
Grifols (GRFS) Q3 2026 Earnings Call Transcript
2026-11-03 03:58 · Yahoo
Grifols Q3 Earnings Call Highlights
2026-11-02 20:12 · Yahoo
Grifols Q3 revenue exceeds estimates as immunoglobulin sales drive growth
2026-11-02 18:20 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.